SCA
IMMX icon

Snowden Capital Advisors’s Immix Biopharma IMMX Stock Holding History

Snowden Capital Advisors’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$103K Hold
10,000
– – ﹤0.01% 1316
2026
Q1 		$91.1K Hold
10,000
– – ﹤0.01% 1261
2025
Q4 		$52.3K Hold
10,000
– – ﹤0.01% 1258
2025
Q3 		$20.9K Buy
+10,000
New +$24K ﹤0.01% 1233

Other funds holding IMMX

JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Snowden Capital Advisors's IMMX Position: Q2 2026 in Review

Snowden Capital Advisors held its Immix Biopharma (IMMX) position steady in Q2 2026 at 10,000 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #1316.

Snowden Capital Advisors first reported a position in IMMX in Q3 2025 and has held it in 4 quarters since. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • Snowden Capital Advisors held 10,000 shares of Immix Biopharma worth $103K as of Q2 2026.
  • Snowden Capital Advisors left its Immix Biopharma share count unchanged in Q2 2026.
  • Immix Biopharma made up ﹤0.01% of Snowden Capital Advisors's portfolio in Q2 2026, its #1316 holding.
  • Snowden Capital Advisors first reported a position in Immix Biopharma in Q3 2025 and has held it in 4 quarters since.
  • 109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.